![]() |
|
|
Vol. 281, Issue 2, 791-798, 1997
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park,
Illinois
Endothelins (ETs) are 21-amino acid peptides that bind to membrane
receptors to initiate pathophysiological effects. Two types of ET
receptors, ETA and ETB, have been identified.
Various ET receptor antagonists are being developed as therapeutic
agents. This report examines the effects of bovine serum albumin (BSA) on the potency of ET receptor antagonists and compares five ET receptor
antagonists. Competition studies show that in the absence of BSA,
A-127722 and L-749329 inhibited ET-1 binding to ETA
receptor with the same IC50 value of 0.09 nM. Addition of
increasing concentrations of BSA incrementally decreased the potency of
the antagonists: in the presence of 5% BSA, the IC50
values increased to 4.3 and 820 nM, respectively. Similarly, addition
of BSA decreased the potency of antagonists in inhibiting
ET-1-stimulated phosphatidylinositol hydrolysis. These results suggest
that serum albumin has profound effects on the potencies of ET receptor
antagonists. FR139317, PD-156707, L-749329, Ro-47-0203 and A-127722
were then selected for direct comparison under identical experimental
conditions with 0.2% BSA. The potency of antagonists was assessed by
binding studies for the determination of IC50 and
Ki values and by ET-1-stimulated phosphatidylinositol hydrolysis and arachidonic acid release for the
determination of IC50 and pA2 values. All five
antagonists inhibited ET binding and the biological effects exerted by
ET in a competitive mode. The Ki values for
A-127722, PD-156707, FR139317, Ro-47-0203 and L-749329 for the
ETA receptor were 0.07, 0.38, 0.80, 3.67 and 33.6 nM,
respectively. A similar hierarchy was revealed by the functional
assays. Our results suggest that the rank order of potency of the
antagonists is A-127722
PD-156707
FR139317 > Ro-47-0203 > L-749329.